LabGenomics Co., Ltd.
Financials
Valuation Metrics
LabGenomics Co., Ltd.'s Market Cap is ₩558B. At end of 2025 it was ₩1344B. Ranked #1663 of 2,436 in KR market (top 68%), #992 of 1,649 on KOSDAQ (top 60%), #183 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 55.75B KRW | KR#1,663/2,436 Sec#183/234 |
| Revenue | 84.19B KRW | KR#1,504/2,436 Sec#94/234 |
| Net Income | -63.71B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 234.96B KRW | KR#1,171/2,436 Sec#83/234 |
| Net Assets | 149.16B KRW | KR#1,110/2,436 Sec#81/234 |
| Employees | 186 | KR#1,141/2,436 Sec#96/234 |
| Value | ||
| P/B | 0.37x | KR#513/2,436 Sec#18/234 |
| P/S | 0.66x | KR#1,115/2,436 Sec#53/234 |
| FCF Yield | -56.81% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -42.71% | KR#2,244/2,436 Sec#193/234 |
| ROA | -27.11% | KR#2,276/2,436 Sec#190/234 |
| Op. Margin | -61.74% | KR#2,263/2,436 Sec#163/234 |
| Revenue Growth | -18.13% | KR#2,033/2,436 Sec#185/234 |
| Financial Health | ||
| Debt Ratio | 157.52% | KR#1,288/2,436 Sec#146/234 |
| FCF | -31.67B KRW | KR#2,011/2,436 Sec#194/234 |
| Cash | 3.86B KRW | KR#2,082/2,436 Sec#191/234 |
| Current Ratio | 1.17x | KR#1,618/2,436 Sec#168/234 |
| Performance | ||
| 1Y Return | -68.31% | KR#2,326/2,436 Sec#221/234 |
| 1M Return | 7.75% | KR#342/2,436 Sec#23/234 |
| From 52W High | -70.95% | KR#2,167/2,436 Sec#200/234 |
| 1Y MDD | -78.84% | KR#2,267/2,436 Sec#207/234 |
| Trading | ||
| Volume | 4,044,855 shares | KR#25/2,436 Sec#3/234 |
| Foreign Own. | 2.05% | KR#1,079/2,436 Sec#106/234 |
| Per Share | ||
| EPS | -858 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,009 KRW | KR#2,023/2,436 Sec#167/234 |
Company Info
Labgenomics, established in 2002 as a specialized genomics molecular diagnostics company and headquartered in Seongnam-si, Gyeonggi-do, was listed on KOSDAQ in 2014. In 2024, the company officially entered the American diagnostic market by acquiring U.S. CLIA labs QDx Pathology Services and IMD, securing a diagnostic service network across the United States. It operates various genomics molecular diagnostics businesses, having commercialized Korea's first Next-Generation Sequencing (NGS)-based non-invasive prenatal testing for fetal abnormalities and established a network of over 3,000 hospitals nationwide.